BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 20541704)

  • 1. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.
    Wang Z; Iwasaki M; Ficara F; Lin C; Matheny C; Wong SH; Smith KS; Cleary ML
    Cancer Cell; 2010 Jun; 17(6):597-608. PubMed ID: 20541704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.
    Muntean AG; Tan J; Sitwala K; Huang Y; Bronstein J; Connelly JA; Basrur V; Elenitoba-Johnson KS; Hess JL
    Cancer Cell; 2010 Jun; 17(6):609-21. PubMed ID: 20541477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
    Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
    Wang GG; Pasillas MP; Kamps MP
    Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional activation by MEIS1A in response to protein kinase A signaling requires the transducers of regulated CREB family of CREB co-activators.
    Goh SL; Looi Y; Shen H; Fang J; Bodner C; Houle M; Ng AC; Screaton RA; Featherstone M
    J Biol Chem; 2009 Jul; 284(28):18904-12. PubMed ID: 19473990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.
    Roychoudhury J; Clark JP; Gracia-Maldonado G; Unnisa Z; Wunderlich M; Link KA; Dasgupta N; Aronow B; Huang G; Mulloy JC; Kumar AR
    Blood; 2015 Apr; 125(16):2544-52. PubMed ID: 25740828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meis1 and pKnox1 bind DNA cooperatively with Pbx1 utilizing an interaction surface disrupted in oncoprotein E2a-Pbx1.
    Knoepfler PS; Calvo KR; Chen H; Antonarakis SE; Kamps MP
    Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14553-8. PubMed ID: 9405651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.
    Velu CS; Chaubey A; Phelan JD; Horman SR; Wunderlich M; Guzman ML; Jegga AG; Zeleznik-Le NJ; Chen J; Mulloy JC; Cancelas JA; Jordan CT; Aronow BJ; Marcucci G; Bhat B; Gebelein B; Grimes HL
    J Clin Invest; 2014 Jan; 124(1):222-36. PubMed ID: 24334453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
    Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
    Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.
    Zhou J; Wu J; Li B; Liu D; Yu J; Yan X; Zheng S; Wang J; Zhang L; Zhang L; He F; Li Q; Chen A; Zhang Y; Zhao X; Guan Y; Zhao X; Yan J; Ni J; Nobrega MA; Löwenberg B; Delwel R; Valk PJ; Kumar A; Xie L; Tenen DG; Huang G; Wang QF
    Leukemia; 2014 Jul; 28(7):1436-48. PubMed ID: 24445817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
    Zeisig BB; Milne T; García-Cuéllar MP; Schreiner S; Martin ME; Fuchs U; Borkhardt A; Chanda SK; Walker J; Soden R; Hess JL; Slany RK
    Mol Cell Biol; 2004 Jan; 24(2):617-28. PubMed ID: 14701735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
    Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
    Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Identification of proteins associated with transcription factors HOXA9 and E2A-PBX1 by tandem affinity purification].
    Shestakova EA; Boutin M; Bourassa S; Bonneil E; Bijl JJ
    Mol Biol (Mosk); 2017; 51(3):490-501. PubMed ID: 28707666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of MLL amino terminal sequences with menin is required for transformation.
    Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
    Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
    Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
    Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
    Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
    Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation.
    Morgado E; Albouhair S; Lavau C
    Blood; 2007 May; 109(9):4020-2. PubMed ID: 17202314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.